Tag: CTCL
The Lancet Publishes Positive Phase III Trial Data of Brentuximab Vedotin...
Data from the randomized Phase III ALCANZA clinical trial evaluating brentuximab vedotin (Adcetris®) in patients with cutaneous T-cell lymphoma (CTCL) were published in the...
Alcanza Trial Demonstrates Highly Statistically Significant Improvement in Rate of Objective...
Results of the phase III Alcanza trial evaluating brentuximab vedotin (Adcetris®; Takeda Pharmaceutical and Seattle Genetics) in patients with cutaneous T-cell lymphoma (CTCL) shows...
Seattle Genetics Completes Enrollment for Phase III Trial Designed to Evaluate...
Seattle Genetics and its collaborator, Takeda Pharmaceutical, have completed patient enrollment in the open label, phase III ALCANZA (NCT01578499) clinical trial. This randomized trial is...
